Abstract:513 Background: There are conflicting reports on the impact of growth factor support in combination with bleomycin on the development of bleomycin associated lung toxicity in various malignancies. In addition, theories remain surrounding the possibility of worsened hematologic toxicity when receiving pegfilgrastim too close to the time of subsequent chemotherapy that is given in consecutive weeks. Here, we aim to evaluate the safety of the use of pegfilgrastim in patients with germ-cell tumor (GCT) undergoing combination chemotherapy containing bleomycin. Methods: The prospectively maintained Indiana University testicular cancer database was queried for patients with metastatic GCT treated between 2010-2023 at Indiana University with chemotherapy containing bleomycin. Safety in patients who received at least one dose of pegfilgrastim were compared to patients who did not receive any doses. Bleomycin lung toxicity was per the discretion of treating physician. Comparison between groups was done using Chi-square tests for categorical variables or Wilcoxon test for continuous variables. Results: 196 patients met eligibility. Median age at diagnosis was 26.7 (range, 20.2-50). Primary site was testis in 95.4%, retroperitoneum in 2.6%, and mediastinum in 2%. 79% of patients included had nonseminomatous germ-cell tumor (NSGCT). IGCCCG risk was good in 146, intermediate in 19, and poor in 31 patients. First-line chemo was BEPX3 in 71% of patients, BEPX3 with EPX1 in 9% of pts, BEPX4 in 10% of patients, and other in 10% of patients. There were 49 patients (25%) who received at least one dose of pegfilgrastim with chemotherapy. There was no statistically significant difference in the type of chemotherapy received, metastatic sites of disease at time of diagnosis, or IGCCCG risk in patients who received pegfilgrastim vs. those who did not. The median number of pegfilgrastim doses received was 2. The median number of doses of bleomycin received was 9 for both patients who received pegfilgrastim and those who did not. In those who received pegfilgrastim, 4 patients developed bleomycin lung toxicity vs. 13 patients who did not receive pegfilgrastim (p=1.000). Of these 17 pts, 9 were diagnosed on symptoms and exam alone, 2 by imaging with symptoms, 2 by imaging without symptoms, 3 on PFTs ordered because of symptoms, and 1 on PFTs alone without symptoms. 3 patients required steroids. There were no fatalities related to pulmonary toxicity. Median nadir ANC in those who received pegfilgrastim was 3350 vs. 800 in those who did not (p<0.0001). Conclusions: The administration of pegfilgrastim with combination chemotherapy containing bleomycin for metastatic GCT did not increase the risk for bleomycin associated lung toxicity. Hematologic toxicity, demonstrated by nadir ANC, was worse in pts who did not receive pegfilgrastim.

Intensive-dose ifosfamide and etoposide with filgrastim for cytoreduction before peripheral blood stem cell collection in patients with advanced ovarian cancer

High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer

Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia to cure advanced ovarian cancer

[High-Dose Etoposide with Granulocyte Colony-Stimulating Factor for Mobilization of Autologous Peripheral Blood Stem/progenitor Cells in Patients with Hematologic Malignancies].

Gemcitabine and Ifosfamide As a Second-Line Treatment for Cisplatin-Refractory Metastatic Urothelial Carcinoma: a Phase II Study

Modified Intraperitoneal Chemotherapy Without Bevacizumab As a First-Line Therapy for Newly Diagnosed Advanced Epithelial Ovarian Cancer-Two Centers Experiences

[Combined Pegylated Liposomal Doxorubicin and Carboplatin in the Treatment of Recurrent Epithelial Ovarian Cancer].

A Phase I Study of Pemetrexed (P) Plus Gemcitabine (G) in Relapsed Ovarian Cancer (oc): Dosing Results and Evidence of Activity.

Pharmacokinetically Guided Phase I Trial of Topotecan and Etoposide Phosphate in Recurrent Ovarian Cancer

Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial

Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study

The Role of High Dose Chemotherapy with Autologous Hematopoietic Cell Transplant in Relapsed/Refractory Ovarian Germ Cell Tumors: A Single Center Experience

[Efficacy and Tolerability of the Combination of Oxaliplatin, Ifosfamide, and Epirubicin in Treatment of Recurrent or Platinum-Resistant Ovarian Epithelial Cancer Patients].

Treatment Tolerance and Side Effects of Intraperitoneal Carboplatin and Dose-Dense Intravenous Paclitaxel in Ovarian Cancer

Higher efficacy of Etoposide + Cytarabine Plus Pegfilgrastim in poorly mobilizing Multiple Myeloma and lymphoma Patients

Dose-Dense Early Postoperative Intraperitoneal Chemotherapy In Ovarian Cancer: Randomized, Phase Ii Trial.

Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma

Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14

[Clinical Study on High-Dose Etoposide with Granulocyte Colony-Stimulating Factor for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Hematologic Malignancies].

Safety of pegfilgrastim in patients with metastatic germ-cell tumor receiving combination chemotherapy containing bleomycin.

High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Salvage Therapy of Relapsed/Refractory Germ Cell Tumors: A Single-Center Experience